Thermo Fisher Scientific Sells Assets to Expedite Life Technologies Acquisition
Thermo Fisher Scientific (California, USA) has signed an agreement with GE Healthcare (St Giles, UK) to sell business assets for $1.06 billion. Thermo Fisher committed to sell its cell culture, gene modulation, and magnetic beads businesses in 2013 to expedite approval of its pending acquisition of Life Technologies by the European Commission.
Thermo Fisher Scientific (California, USA) has signed an agreement with GE Healthcare (St Giles, UK) to sell business assets for $1.06 billion. Thermo Fisher committed to sell its cell culture, gene modulation, and magnetic beads businesses in 2013 to expedite approval of its pending acquisition of Life Technologies by the European Commission.
The combined revenue of the three businesses, which form part of Thermo Fisher’s Analytical Technologies Segment, is estimated to be $250 million in 2013. Kieran Murphy, president and CEO of GE Healthcare’s Life Sciences division, said: “In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing.” He added: “By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera, a key part of their production process.”
For further information visit www.gehealthcare.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
